一种多菌株益生菌配方可缓解中年和老年人的慢性便秘:一项随机,双盲,安慰剂对照试验
Rui Xiao1, Yeping He2, Xuhua Mao3
1State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, Jiangsu, PR China; School of Food Science and Technology, Jiangnan University, Wuxi 214122, Jiangsu, PR China.
Clinical nutrition (Edinburgh, Scotland)
|February 26, 2026
概括
28天的多菌株益生菌显著改善了成年人的慢性便秘症状,增加了肠道排便,减少了膨胀. 这种干预也有利地改变了肠道微生物群和短链脂肪酸通路.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 营养科学 营养科学
背景情况:
- 慢性便秘影响中年和老年人,目前治疗的疗效和副作用有限.
- 益生菌为控制便秘提供了一种安全而有前途的替代方案.
研究的目的:
- 评估28天的多菌株益生菌干预治疗中老年和老年人的慢性便秘.
- 评估临床改善和机械变化,包括肠道微生物群和便代谢物.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及132名患有慢性便秘的成年人.
- 主要终点:每周一次完全自发性排便 (CSBMs). 二级终点:便形状,便秘症状,胀气,以及多种药物分析.
- 响应者定义:第4周的CSBM≥3和从基线增加≥1.
主要成果:
- 与安慰剂相比,益生菌组的CSBMs (4.53 vs 2.40) 显著增加,胀气减少 (P < 0.0001).
- 微生物群分析显示,有益细菌 (Faecalibacterium,Lactobacillus,Bifidobacterium) 的增加,有害细菌的减少.
- 观察到便中酸盐和丁酸盐水平增加,与改善的CSBM相关联.
结论:
- 一种为期28天的多菌株益生菌有效治疗中老年人和老年人的慢性便秘.
- 益生菌改善了肠道排便的频率,缓解了胀气,并积极调节了肠道微生物群和SCFA生产.
- 支持使用这种益生菌作为治疗慢性便秘的营养干预措施.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
995
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
995
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
658
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
658
Chronic Bowel Disorders: Introduction
853
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
853
Drugs Affecting GI Tract Motility: Other Laxatives
1.2K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.2K
Drugs for Treatment of Diarrhea-Predominant IBS
798
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
798
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
673
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
673


